

Please type a plus sign (+) inside this box →



4-21-04

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/659,800
Filing Date	September 10, 2003
First Named Inventor	FARESE JR., ROBERT V.
Group Art Unit	1632
Examiner Name	To Be Assigned
Attorney Docket Number	UCAL-105CIP2CON2
Total Number of Pages in This Submission	

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1) PTO/SB/08A (2 pgs.) 2) EP Search Report 3) 8 Cited References 4) Return Postcard
Remarks		


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Signing Attorney/Agent (Reg. No.)	PAULA A. BORDEN, 42,344 BOZICEVIC, FIELD & FRANCIS LLP
Signature	
Date	April 19, 2004

EXPRESS MAIL LABEL NO. EV405281330US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. EV405281330US

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(e) Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	UCAL-105CIP2CON2
	First Named Inventor	FARESE JR., ROBERT V.
	Application Number	10/659,800
	Confirmation No.	7565
	Filing Date	September 10, 2003
	Group Art Unit	1632
	Examiner Name	
Title: "DIACYLGLYCEROL O-ACYLTRANSFERASE"		

Sir:

Applicants submit herewith patents and/or publications which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. While this Statement may be "material" pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any patent, publication, or other information referred to therein is "prior art" for this invention unless specifically designated as such. A listing of patents and/or publications is shown on enclosed Form PTO-SB/08A and a copy of each patent and/or publication is also enclosed.


Each item of information contained in the Information Disclosure Statement filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement (37 C.F.R. 1.97(e)(1)). A copy of the communication is enclosed for the Examiner's convenience.

The Examiner is requested to make the citations listed on the enclosed PTO-SB/08A of record in this application. Applicants would appreciate the Examiner initialing and returning the initialed copy of form PTO-SB/08A, indicating the references have been considered and made of record herein.

No fee is believed due as this statement is being submitted within three months of the mailing date of the enclosed foreign communication. However, if it is determined that fees are required, the Commissioner is hereby authorized to charge any necessary fees associated with this communication or credit any overpayment to Deposit Account No. 50-0815, Order No. UCAL-105CIP2CON2.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: Apr. 19, 2004

By: 
Paula A. Borden, Reg. No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/659,800
		Filing Date	September 10, 2003
		First Named Inventor	FARESE JR., ROBERT V.
		Group Art Unit	1632
Sheet 2 of 2	Examiner Name		
		Attorney Docket Number	UCAL-105CIP2CON2

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		FARESE, FV JR., "Acyl CoA: cholesterol acyltransferase genes and knockout mice" Current Opinion in Lipidology, Vol. 9, No. 2, April 1998, pgs. 119-123	
		FRENTZEN M. "Acyltransferases from basic science to modified seed oils", Fett- Lipid, Wiley - VCH Verlag, Weinham, DE, Vol. 100, No. 4/5, May 1998, pgs. 161-166	
		WILSON, R. F. et al., "Recent Developments in the molecular biochemistry and genetics of diacylglycerol acyltransferase from soybean" Seed Oils for the Future, AOCS press, Champaign, IL, US, 1992, pgs. 116-135	
		TABATA N. et al., "Xanthohumols diacylglycerol acyltransferase inhibitors, from Humulus Lupulus", Phytochemistry, Pergamon Press, GB, Vol. 46, No. 4, October 1997, pgs. 683-687	
		ZOU et al., "The Arabidopsis thaliana TAG1 mutant has a mutation in a diacylglycerol acyltransferase gene", Plant Journal, Blackwell Scientific Publications, Oxford GB, Vol. 19, No. 6, September 1999, pgs. 645-653	
		SMITH S J et al., "Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat", Nature America, New York, US, Vol. 25, No. 1, May 2000, pgs. 87-90	
		CHEN HC et al., "Increased insulin and leptin sensitivity in mice lacking acyl CoA: diacylglycerol acyltransferase I "The Journal of Clinical Investigation" Vol. 109, No. 8, April 2002, pgs. 1049-1055	
		BUHMAN KIMBERLY K. et al., DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis" The Journal of Biological Chemistry", U.S. July 12, 2002, Vol. 277, No. 28, July 12, 2002, pgs. 25474-25479	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.